Disease · MONDO_0100163

COVID-19–associated multisystem inflammatory syndrome in children

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. COVID-19–associated multisystem inflammatory syndrome in children. Diseases, record MONDO_0100163. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0100163

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: COVID-19–associated multisystem inflammatory syndrome in children; Open Targets
Open Targets ID: MONDO_0100163; Open Targets
Other names: COVID-19 -related paediatric inflammatory multisystem syndrome, COVID-19 -related pediatric inflammatory multisystem syndrome, COVID-19 Kawasaki-like syndrome, MIS-C, PIMS, PIMS-TS, PMIS, SARS-CoV-2 Kawasaki-like syndrome, multisystem inflammatory syndrome in children, multisystem inflammatory syndrome in children associated with COVID-19, multisystem inflammatory syndrome in children associated with coronavirus disease 2019, paediatric inflammatory multisystem syndrome, paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, paediatric multi-system inflammatory syndrome potentially associated with COVID-19, paediatric multisystem inflammatory syndrome, pediatric inflammatory multisystem syndrome, pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2, pediatric multi-system inflammatory syndrome potentially associated with COVID-19, pediatric multisystem inflammatory syndrome; Open Targets
Disease Ontology: DOID:0080711; Disease Ontology
NCI Thesaurus: C172127; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 27 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ANAKINRA	CHEMBL1201570	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
HUMAN IMMUNOGLOBULIN G	CHEMBL1201599		Phase 3	ClinicalTrials.gov	2	2	1	Drugs and targets
METHYLPREDNISOLONE	CHEMBL650	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ASPIRIN	CHEMBL25	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
AZITHROMYCIN	CHEMBL529	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BALOXAVIR MARBOXIL	CHEMBL4297503	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BARICITINIB	CHEMBL2105759	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BETAMETHASONE	CHEMBL632	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
BETAMETHASONE SODIUM PHOSPHATE	CHEMBL1200762	Small molecule	Phase 3	ClinicalTrials.gov	1	1	0	Drugs and targets
CASIRIVIMAB	CHEMBL4650248	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets32

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	9	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
CHRNA3	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 partial agonist	Phase 2	https://conductscience.org/library/genes/1136	Drugs and targets
CHRNB4	Neuronal acetylcholine receptor; alpha3/beta4	1	Neuronal acetylcholine receptor; alpha3/beta4 partial agonist	Phase 2	https://conductscience.org/library/genes/1143	Drugs and targets
CYP3A4	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/1576	Drugs and targets
CYP3A43	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/64816	Drugs and targets
CYP3A5	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/1577	Drugs and targets
CYP3A7	Cytochrome P450 3A	1	Cytochrome P450 3A inhibitor	Phase 3	https://conductscience.org/library/genes/1551	Drugs and targets
IL1R1	Interleukin-1 receptor type 1	1	Interleukin-1 receptor antagonist	Phase 3	https://conductscience.org/library/genes/3554	Drugs and targets
IL6R	Interleukin-6 receptor subunit alpha	1	Interleukin-6 receptor alpha subunit inhibitor	Phase 3	https://conductscience.org/library/genes/3570	Drugs and targets
JAK1	Tyrosine-protein kinase JAK1	1	Tyrosine-protein kinase JAK1 inhibitor	Phase 3	https://conductscience.org/library/genes/3716	Drugs and targets

1 to 10 of 32

See all 32 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04898231	MIS-C Comparative Effectiveness Study	Phase 2/3	73	2025-11-04	Multisystem Inflammatory Syndrome-Children	ANAKINRA, INFLIXIMAB, METHYLPREDNISOLONE	Its record names the disease	ClinicalTrials.gov
NCT04381936	Randomised Evaluation of COVID-19 Therapy	Phase 3	70,000		Pneumonia	ANAKINRA, ASPIRIN, AZITHROMYCIN, BALOXAVIR MARBOXIL, BARICITINIB, CASIRIVIMAB, COLCHICINE, DEXAMETHASONE, EMPAGLIFLOZIN, HYDROXYCHLOROQUINE, IMDEVIMAB, LOPINAVIR, METHYLPREDNISOLONE, MOLNUPIRAVIR, NIRMATRELVIR, OSELTAMIVIR, RITONAVIR, SOTROVIMAB, TOCILIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT04826588	Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)	Phase 3	76		Paediatric Inflammatory Multisystem Syndrome-Temporally Associated With SARS-CoV-2 (PIMS-TS)	HUMAN IMMUNOGLOBULIN G, METHYLPREDNISOLONE SODIUM SUCCINATE	Its record names the disease	ClinicalTrials.gov
NCT05022303	AT1001 for the Treatment of COVID-19 Related MIS-C	Phase 2	12		Covid19, Multisystem Inflammatory Syndrome in Children	LARAZOTIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT04456439	Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)				Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)	REMESTEMCEL-L	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials36

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40886716	RESULT	1	PubMed
40383127	RESULT	1	PubMed
38296965	RESULT	1	PubMed
37865101	RESULT	1	PubMed
37060915	RESULT	1	PubMed
36746174	RESULT	1	PubMed
35908569	RESULT	1	PubMed
35151397	RESULT	1	PubMed
34800427	RESULT	1	PubMed
34672950	RESULT	1	PubMed

1 to 10 of 36

See all 36 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0100163

GET https://conductscience.org/api/diseases/v1/MONDO_0100163/drugs?page=2

API reference For AI assistants